Ftse Mib
33.772,39
-0,04%
DAX
19.884,75
-0,57%
S&P 500
5.948,33
1,38%
NASDAQ
19.683,98
1,61%
Bitcoin
96.759,48
-0,72%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Avalo Therapeutics Inc (AVTX) Avalo Therapeutics Inc (AVTX) Notizie

Avalo Therapeutics Inc

AVTX
9,22
0,14 (1,54%)
Ultimo aggiornamento: 19:13:35
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
05/12/202413:03EDGAR2Form 8-K - Current report
14/11/202418:05EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
12/11/202413:30EDGAR2Form 8-K - Current report
12/11/202413:00GLOBEAvalo Therapeutics Receives $69.4 Million in Proceeds from..
11/11/202413:00GLOBEAvalo Therapeutics to Present at Upcoming Investor..
07/11/202423:00EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
07/11/202413:20EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/11/202413:17EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/11/202413:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202413:02EDGAR2Form 8-K - Current report
07/11/202413:00GLOBEAvalo Reports Third Quarter 2024 Financial Results and..
08/10/202413:13EDGAR2Form 8-K - Current report
08/10/202413:00GLOBEAvalo Announces First Patient Dosed in Phase 2 LOTUS Trial..
08/10/202402:06EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
09/9/202413:22EDGAR2Form 8-K - Current report
04/9/202413:01EDGAR2Form 8-K - Current report
04/9/202413:00GLOBEAvalo Announces Participation in September Investor..
23/8/202422:05EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
14/8/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202422:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202422:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202422:01EDGAR2Form 8-K - Current report
14/8/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/8/202413:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/8/202413:01EDGAR2Form 8-K - Current report
12/8/202413:00GLOBEAvalo Reports Second Quarter 2024 Financial Results and..
06/8/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
05/8/202422:36EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
30/7/202422:01EDGAR2Form 8-K - Current report
29/7/202422:08EDGAR2Form S-3/A - Registration statement under Securities Act of..
16/7/202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/7/202422:17EDGAR2Form 3 - Initial statement of beneficial ownership of..
16/7/202413:36EDGAR2Form 8-K - Current report
16/7/202413:00GLOBEAvalo Therapeutics Announces Appointment of Dr. Mittie Doyle..
11/7/202422:24EDGAR2Form S-3/A - Registration statement under Securities Act of..
11/7/202422:12EDGAR2Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
09/7/202413:17EDGAR2Form 8-K - Current report
24/6/202422:01GLOBEAvalo Therapeutics Announces Appointment of Paul Varki as..
17/6/202413:30GLOBEAvalo to Present at the Oppenheimer Novel Targets in..
07/6/202413:01EDGAR2Form PRE 14A - Other preliminary proxy statements
06/6/202422:03EDGAR2Form S-3 - Registration statement under Securities Act of..
03/6/202413:20EDGAR2Form 8-K/A - Current report: [Amend]
23/5/202422:01EDGAR2Form 8-K - Current report
13/5/202418:38EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/5/202413:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202413:30EDGAR2Form 8-K - Current report
13/5/202413:30GLOBEAvalo Reports First Quarter 2024 Financial Results and..
02/4/202413:00GLOBEAvalo Therapeutics Appoints Biotech Leaders to Board of..
Apertura: 9,10 Min: 8,67 Max: 9,325
Chiusura: 9,08

La tua Cronologia

NASDAQ
AVTX
Avalo Therapeutics
NASDAQ
ERET
iShares Environmentally ...
LATK
CCMUSDT
Car Coin
NASDAQ
CBUS
Cibus
BIT
F38451
Vontobel Financial Produ...
BIT
S24910
SG ISSUER
BITMOT
980749
Intsanpaolo Tf 4,5% Ap25...
BIT
LINKXC
Investlinx Icav
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network